Fairmount Funds Management LLC
13F Reported Value
ⓘ$1.4B
Holdings
12
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Fairmount Funds Management LLC disclosed 12 positions worth $1.4B in its Form 13F-HR for Q1 2026, led by $DMRA (Damora Therapeutics, Inc.) at 16.3% of the equity portfolio, followed by $DNTH and $COGT. During the quarter the fund opened 1 new position and exited 2 — including a new stake in $DMRA and a full exit from $NUVL. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Fairmount Funds Management LLC’s Form 13F-HR filing with the SEC under CIK 1802528.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$225.7M8,713,000 sh - 26.8#2,490
Quality
$212.9M2,537,191 sh - —
Quality
$211.8M5,503,418 sh - —
Quality
$202.7M4,018,101 sh - —
Quality
$181.7M3,705,262 sh - 30.5
Quality
$76.6M3,914,458 sh - —
Quality
$72.7M1,855,644 sh - —
Quality
$64.0M4,553,494 sh - 28.0
Quality
$50.5M2,747,866 sh - 14.4
Quality
$46.1M2,359,025 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Damora Therapeutics, Inc.$DMRA | — | $225.7M | 8,713,000 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8#2,490 | $212.9M | 2,537,191 |
 Cogent Biosciences, Inc.$COGT | — | $211.8M | 5,503,418 |
 Spyre Therapeutics, Inc.$SYRE | — | $202.7M | 4,018,101 |
 Oruka Therapeutics, Inc.$ORKA | — | $181.7M | 3,705,262 |
 Viridian Therapeutics, Inc.\DE$VRDN | 30.5 | $76.6M | 3,914,458 |
 Enliven Therapeutics, Inc.$ELVN | — | $72.7M | 1,855,644 |
 Jade Biosciences, Inc.$JBIO | — | $64.0M | 4,553,494 |
 CRESCENT BIOPHARMA, INC.$CBIO | 28.0 | $50.5M | 2,747,866 |
 Zenas BioPharma, Inc.$ZBIO | 14.4 | $46.1M | 2,359,025 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Fairmount Funds Management LLC's 12 positions.
Showing top 10 of 12 holdings.
Sector Allocation
Healthcare
$1.4B
Full Holdings — Fairmount Funds Management LLC (Q1 2026)
All 12 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $DMRA | Damora Therapeutics, Inc. | $225.7M | 16.3% | NEW | — |
| 2 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $212.9M | 15.4% | +19% | 26.8 |
| 3 | $COGT | Cogent Biosciences, Inc. | $211.8M | 15.3% | -39% | — |
| 4 | $SYRE | Spyre Therapeutics, Inc. | $202.7M | 14.6% | +0% | — |
| 5 | $ORKA | Oruka Therapeutics, Inc. | $181.7M | 13.1% | +0% | — |
| 6 | $VRDN | Viridian Therapeutics, Inc.\DE | $76.6M | 5.5% | +0% | 30.5 |
| 7 | $ELVN | Enliven Therapeutics, Inc. | $72.7M | 5.3% | -50% | — |
| 8 | $JBIO | Jade Biosciences, Inc. | $64.0M | 4.6% | +0% | — |
| 9 | $CBIO | CRESCENT BIOPHARMA, INC. | $50.5M | 3.6% | +0% | 28 |
| 10 | $ZBIO | Zenas BioPharma, Inc. | $46.1M | 3.3% | +7% | 14.4 |
| 11 |  $APGE | Apogee Therapeutics, Inc. | $25.1M | 1.8% | -85% | — |
| 12 |  $IKT | Inhibikase Therapeutics, Inc. | $14.5M | 1.1% | +0% | — |
New Positions (1)
$DMRA Damora Therapeutics, Inc.$225.7M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Fairmount Funds Management LLC including:
Track Fairmount Funds Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Fairmount Funds Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Fairmount Funds Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Fairmount Funds Management LLC (SEC CIK: 1802528), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Fairmount Funds Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.